EurekAlert! Cancer Research

News Releases

Updates every hour. Last Updated: 20-Oct-2026 10:16 ET (20-Oct-2026 14:16 GMT/UTC)

5-Oct-2026

Theresa Werner, MD, named chief of the Division of Oncology

Huntsman Cancer Institute
Business Announcement

The nationally recognized physician-scientist will lead medical oncology at Huntsman Cancer Institute and the University of Utah, advancing innovative care, clinical research, and training to improve patient outcomes.

5-Oct-2026

ACP recommends hormonal therapy as a first-line treatment for menopausal vasomotor symptoms

American College of Physicians
Peer-Reviewed Publication

The American College of Physicians (ACP) recommends estrogen in combination with progestogen (for females with a uterus) or estrogen monotherapy (for females without a uterus) as first-line treatment for perimenopausal and postmenopausal females experiencing menopausal vasomotor symptoms (VMS), which consist of hot flashes and night sweats.

Journal: Annals of Internal Medicine

5-Oct-2026

Cigarette smoke may prime lung stem cells for different types of lung cancer

Johns Hopkins Medicine
Peer-Reviewed Publication

Chronic exposure to cigarette smoke may reprogram different populations of lung stem cells, which maintain and repair lung tissue, in ways that make them vulnerable to specific cancer-causing gene alterations and ultimately helps determine the type of lung cancer that develops.

Journal: Proceedings of the National Academy of Sciences
Funder: Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, The Hodson Trust, American Lung Association Lung Cancer Discovery Award, the Evelyn Grollman Glick Scholar Award, Johns Hopkins University Discovery Award, TEDCO, National Institute of Environmental Health Sciences, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Support, Van Andel Research Institute

5-Oct-2026

Model traces C. diff spread in hospital oncology units

North Carolina State University
Peer-Reviewed Publication

In a new study, researchers modeled the transmission of Clostridioides difficile (C. diff) infections among patients in hospital cancer units. They found that most new infections were introduced by patients who were infected but not symptomatic at the time of admission, rather than by patients who were infected and symptomatic. The model provides a clearer picture of C. diff transmission events in oncology wards and could help inform protocols aimed at preventing future disease transmission in a highly susceptible population.

Journal: Infection Control and Hospital Epidemiology
Funder: Centers for Disease Control and Prevention, National Science Foundation Graduate Research Fellowship Program

5-Oct-2026

Mount Sinai Tisch Cancer Center cuts clinical trial data-entry time by more than half with real-time EHR-to-EDC technology

The Mount Sinai Hospital / Mount Sinai School of Medicine
Business Announcement

The Mount Sinai Tisch Cancer Center has brought its electronic health record (EHR)-to-electronic data capture (EDC) technology into routine use across its cancer research program. Powered by IgniteData’s Archer platform and integrated with Epic, the technology has produced early results, reducing clinical trial data-entry time by more than half while improving the efficiency and reliability of research data collection.

5-Oct-2026

Aging supports the 11th International Cell Senescence Association Conference

Impact Journals LLC
Meeting Announcement

BUFFALO, NY — October 5, 2026 — Aging is pleased to support the 11th International Cell Senescence Association (ICSA) Conference, taking place November 3–5, 2026, at Seoul National University’s Siheung Convention Center in South Korea.

5-Oct-2026

Lukas Chavez from Sanford Burnham Prebys named recipient of 2026 AWS Children’s Health Innovation Award

Sanford Burnham Prebys
Grant and Award Announcement

The award will support the Center for Data Science and Artificial Intelligence in developing an AI-powered system to help identify personalized treatment options for children with cancer.

5-Oct-2026

Alliance Foundation Trials and Natera announce AFT-70 Navigate: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with SignateraTM MRD-Guided CDK4/6 Inhibitor Therapy in ER+/HER2− Breast Canc

Alliance for Clinical Trials in Oncology
Business Announcement

Alliance Foundation Trials, LLC (AFT), a national leader in conducting innovative, practice-changing cancer clinical trials, and Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of AFT-70 NAVIGATE, a randomized phase III trial evaluating a novel molecular residual disease (MRD)-guided treatment strategy for patients with intermediate and high-risk ER-positive/HER2-negative early breast cancer. The trial is sponsored and led by AFT, with collaboration and co-funding from Natera and Genentech, a member of the Roche Group.

Funder: Natera and Genentech, a member of the Roche Group

5-Oct-2026

Oncolytic viruses and car cells: A modular platform to overcome solid tumor barriers

Immunity & Inflammation
Peer-Reviewed Publication

Solid tumors resist CAR cell therapy through antigen heterogeneity, poor infiltration, and an immunosuppressive microenvironment. A new review argues that oncolytic viruses and CAR cells should be co-designed as an integrated, self-amplifying therapeutic system rather than simply combined. The authors describe how oncolytic viruses can install new targets, remodel the tumor microenvironment, and deliver local immune support, outlining engineering strategies, translational challenges, and future directions for next-generation solid tumor immunotherapy.

Journal: Immunity & Inflammation
Funder: National Cancer Institute

4-Oct-2026

KRAS inhibition combined with CTLA-4 blockade overcomes immunotherapy resistance in KRAS-mutant gastric cancer

Science China Press
Peer-Reviewed Publication

A team led by researchers at Peking University Cancer Hospital & Institute reports that combining targeted KRAS inhibition with CTLA-4 immune checkpoint blockade overcomes the immunosuppressive microenvironment that renders KRAS-mutant gastric adenocarcinoma resistant to PD-1 immunotherapy. In a genetically faithful, immunocompetent mouse model of KRAS^G12D-driven gastric cancer, the combination suppressed TGF-beta signaling, impaired regulatory T cell function and elicited effective anti-tumor immunity. The study, published in Science China Life Sciences, provides a preclinical rationale for CTLA-4-based combination immunotherapy in this molecularly defined subset of patients.

Journal: Science China Life Sciences